Answers are grounded in this paper and cite their sources.
The highly immunosuppressive tumor microenvironment significantly restricts T-cellmediated antitumor responses, thereby severely limiting the efficacy of immunotherapy.Herein, a mitochondria-targeted nanozyme platform rich in copper ions is rationally designed and engineered for cuproptosis/apoptosis co-activated immunogenic cell death (ICD), and subsequently enhances immunotherapy.In this structure, the disulfiram-copper complex leverages its unique transmembrane transport capability to precisely deliver copper ions into the tumor cells, facilitating the in situ concurrent cuproptosis and apoptosis via mitochondrial dysfunction and enhanced oxidative stress.This combined induction of cuproptosis and apoptosis triggers a pronounced ICD, evidenced by the significant release of DAMPs, such as CRT, HMGB1, and ATP.These signals promote dendritic cell maturation, antigen presentation, and cytotoxic T lymphocyte activation, collectively reprogramming the immunosuppressive tumor microenvironment into an immune activation state.Moreover, the system strategically leverages therapy-induced upregulation of PD-L1 to potentiate immune checkpoint blockade.When integrated with αPD-1 treatment, the rate of tumor suppression attained 96.8%, significantly exceeding the 49.2% effectiveness observed with αPD-1 monotherapy.Therefore, the immunostimulatory strategy that leverages cuproptosis to modulate the tumor microenvironment represents an innovative and promising approach that can effectively enhance the efficacy of immune response in cancer immunotherapy.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: